CD52 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CD52" in English language version.

Last modified: 05:10:42, 2 June 2025 (UTC)

Ref.Un. Ref.Website

Global rank English rank

77nih.gov

5^th place

66doi.org

2^nd place

31ensembl.org

630^th place

326^th place

22hdl.handle.net

66^th place

34^th place

22semanticscholar.org

15^th place

8^th place

11ox.ac.uk

541^st place

356^th place

11thelancet.com

2,615^th place

3,403^rd place

doi.org (Global: 2^nd place; English: 2^nd place)

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (September 2002). "Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab". Blood. 100 (5): 1715–20. doi:10.1182/blood.V100.5.1715.h81702001715_1715_1720. PMID 12176892.
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW (February 2003). "Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation". Blood. 101 (4): 1422–9. doi:10.1182/blood-2002-04-1093. PMID 12393688.
Hale G, Waldmann H (2000). "From Laboratory to Clinic : The Story of CAM PA TH-1". Methods Mol. Med. 40: 243–66. doi:10.1385/1-59259-076-4:243. ISBN 978-1-59259-076-6. PMID 21337094.{{cite journal}}: CS1 maint: periodical has ISBN (link)
Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (April 2007). "Expression of CD52 in peripheral T-cell lymphoma". Haematologica. 92 (4): 566–7. doi:10.3324/haematol.10767. hdl:11585/51398. PMID 17488672.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial". Lancet. 380 (9856): 1829–39. doi:10.1016/S0140-6736(12)61768-1. hdl:2078.1/124398. PMID 23122650. S2CID 5736696.^{[unreliable medical source?]}
Cohen, Jeffrey; Coles A; Arnold D (24 November 2012). "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial". The Lancet. 380 (9856): 1819–1828. doi:10.1016/S0140-6736(12)61769-3. PMID 23122652. S2CID 15841906. Retrieved 28 December 2012.

ensembl.org (Global: 630^th place; English: 326^th place)

may2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000169442 – Ensembl, May 2017

hdl.handle.net (Global: 66^th place; English: 34^th place)

Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (April 2007). "Expression of CD52 in peripheral T-cell lymphoma". Haematologica. 92 (4): 566–7. doi:10.3324/haematol.10767. hdl:11585/51398. PMID 17488672.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial". Lancet. 380 (9856): 1829–39. doi:10.1016/S0140-6736(12)61768-1. hdl:2078.1/124398. PMID 23122650. S2CID 5736696.^{[unreliable medical source?]}

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (September 2002). "Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab". Blood. 100 (5): 1715–20. doi:10.1182/blood.V100.5.1715.h81702001715_1715_1720. PMID 12176892.
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW (February 2003). "Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation". Blood. 101 (4): 1422–9. doi:10.1182/blood-2002-04-1093. PMID 12393688.
Hale G, Waldmann H (2000). "From Laboratory to Clinic : The Story of CAM PA TH-1". Methods Mol. Med. 40: 243–66. doi:10.1385/1-59259-076-4:243. ISBN 978-1-59259-076-6. PMID 21337094.{{cite journal}}: CS1 maint: periodical has ISBN (link)
Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (April 2007). "Expression of CD52 in peripheral T-cell lymphoma". Haematologica. 92 (4): 566–7. doi:10.3324/haematol.10767. hdl:11585/51398. PMID 17488672.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial". Lancet. 380 (9856): 1829–39. doi:10.1016/S0140-6736(12)61768-1. hdl:2078.1/124398. PMID 23122650. S2CID 5736696.^{[unreliable medical source?]}
Cohen, Jeffrey; Coles A; Arnold D (24 November 2012). "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial". The Lancet. 380 (9856): 1819–1828. doi:10.1016/S0140-6736(12)61769-3. PMID 23122652. S2CID 15841906. Retrieved 28 December 2012.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

ox.ac.uk (Global: 541^st place; English: 356^th place)

users.path.ox.ac.uk

Hale G, Waldmann H (2000). "From Laboratory to Clinic : The Story of CAM PA TH-1". Methods Mol. Med. 40: 243–66. doi:10.1385/1-59259-076-4:243. ISBN 978-1-59259-076-6. PMID 21337094.{{cite journal}}: CS1 maint: periodical has ISBN (link)

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial". Lancet. 380 (9856): 1829–39. doi:10.1016/S0140-6736(12)61768-1. hdl:2078.1/124398. PMID 23122650. S2CID 5736696.^{[unreliable medical source?]}
Cohen, Jeffrey; Coles A; Arnold D (24 November 2012). "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial". The Lancet. 380 (9856): 1819–1828. doi:10.1016/S0140-6736(12)61769-3. PMID 23122652. S2CID 15841906. Retrieved 28 December 2012.

thelancet.com (Global: 2,615^th place; English: 3,403^rd place)

Cohen, Jeffrey; Coles A; Arnold D (24 November 2012). "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial". The Lancet. 380 (9856): 1819–1828. doi:10.1016/S0140-6736(12)61769-3. PMID 23122652. S2CID 15841906. Retrieved 28 December 2012.

CD52 (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 630th place; English: 326th place)